TABLE IV. Imbalances at baseline of the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial in the six prognostic factors in the Rassi score, which is used to assess risk of death in chronic Chagas cardiomyopathy.
| Benznidazole (n = 1431) | Placebo (n = 1423) | |
|---|---|---|
| Male sex | 50.7% | 47.9% |
| Low QRS voltage on electrocardiography | 13.3% | 12.1% |
| Complex ventricular arrhythmia | 15.4% | 13.3% |
| Wall motion abnormalitya | 38.3% | 37.6% |
| Evidence of cardiomegaly on radiography | NA | NA |
| NYHA functional class III | 2.7% | 2.3% |
a: echocardiography was done less than 1 year before randomization; NA: not available; NYHA: New York Heart Association. Adapted from Morillo et al. (2015).